文献速递胸部肿瘤头颈与中枢神经肿瘤骨软组织肉瘤与黑色素瘤

免疫检查点机制概览:为肿瘤免疫治疗联合方案理性设计提供依据

Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
PubMed 文献 · Ann Oncol · 2018-01-01

本文综述了CTLA-4、PD-1、TIGIT、TIM-3和LAG-3等主要免疫检查点的机制细节与差异,指出已有6种检查点阻断药物获批用于多种实体瘤和血液肿瘤,但仅部分患者应答;基于检查点机制差异及肿瘤微环境中表达差异选择联合方案,可能在特定癌种中产生协同效应并具有可控安全性。

要点

  • CTLA-4、PD-1、TIGIT、TIM-3和LAG-3是癌症免疫治疗最常靶向的检查点受体。
  • 已有1种CTLA-4阻断剂、2种PD-1阻断剂和3种PD-L1阻断剂获批用于多种癌症。
  • 检查点阻断的主要问题仅部分患者应答,免疫激活不足被认为是低应答率主因之一。

核心结论

  • 基于检查点机制差异及肿瘤微环境中检查点及其配体表达差异选择的联合方案,可能在特定癌种中产生协同效应并具有可控安全性。

研究设计与样本

  • 综述,讨论主要免疫检查点的机制细节及靶向差异,以帮助设计最优检查点阻断联合方案。

主要发现

  • 检查点阻断在癌症治疗中取得巨大成功,但仅部分患者应答,免疫激活不足被认为是低应答率主因之一。
  • 检查点联合在黑色素瘤中成功但伴显著不良事件。
  • 基于机制差异和表达差异选择的联合方案可能在特定癌种中产生协同效应并具有可控安全性。

关键数值与推荐

  • CTLA-4、PD-1、TIGIT、TIM-3和LAG-3是癌症免疫治疗最常靶向的检查点。
  • 6种药物获批:1种CTLA-4阻断剂(ipilimumab)、2种PD-1阻断剂(nivolumab和pembrolizumab)、3种PD-L1阻断剂(atezolizumab、avelumab和durvalumab)。
  • 获批用于黑色素瘤、肺癌、头颈癌、膀胱癌、Merkel细胞癌等实体瘤及经典霍奇金淋巴瘤等血液肿瘤。

临床怎么用

  • 基于检查点机制差异及肿瘤微环境中检查点及其配体表达差异选择联合方案,可能获得协同效应和可控安全性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Checkpoint receptor blockers, known to act by blocking the pathways that inhibit immune cell activation and stimulate immune responses against tumor cells, have been immensely successful in the treatment of cancer. Among several checkpoint receptors of immune cells, cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), T-cell immunoglobulin and ITIM domain (TIGIT), T-cell immunoglobulin-3 (TIM-3) and lymphocyte activation gene 3 (LAG-3) are the most commonly targeted checkpoints for cancer immunotherapy. Six drugs including one CTLA-4 blocker (ipilimumab), two PD-1 blockers (nivolumab and pembrolizumab) and three PD-L1 blockers (atezolizumab, avelumab and durvalumab) are approved for the treatment of different types of cancers including both solid tumors such as melanoma, lung cancer, head and neck cancer, bladder cancer and Merkel cell cancer as well as hematological tumors such as classic Hodgkin's lymphoma. The main problem with checkpoint blockers is that only a fraction of patients respond to the therapy. Insufficient immune activation is considered as one of the main reason for low response rates and combination of checkpoint blockers has been proposed to increase the response rates. The combination of checkpoint blockers was successful in melanoma but had significant adverse events. A combination that is selected based on the mechanistic differences between checkpoints and the differences in expression of checkpoints and their ligands in the tumor microenvironment could have a synergistic effect in a given cancer subtype and also have a manageable safety profile. This review aims to help in design of optimal checkpoint blocker combinations by discussing the mechanistic details and outlining the subtle differences between major checkpoints targeted for cancer immunotherapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Rotte A, Jin JY, Lemaire V, et al. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018. PMID: 29069302. doi:10.1093/annonc/mdx686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。